Panel backs compulsory licence on cancer drug3 min read . Updated: 11 Sep 2013, 12:40 AM IST
If the DIPP approves the recommendation, it will be India’s second compulsory licence
New Delhi: An expert committee on compulsory licensing has recommended that the department of industrial policy and promotion (DIPP) issue a compulsory licence for the manufacture of Bristol-Myers Squibb Co.’s anti-cancer drug Dasatinib to two companies.
Select your Category